Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
Curr Opin Virol. 2013 Jun;3(3):343-51. doi: 10.1016/j.coviro.2013.04.007. Epub 2013 Jun 15.
With a few exceptions, vaccines for viruses that cause hemorrhagic fever remain unavailable or lack well-documented efficacy. In the past decade this has not been due to a lack of the ability to develop vaccine platforms against highly pathogenic viruses, but rather the lack of will/interest to invest in platforms that have the potential to become successful vaccines. The two exceptions to this are vaccines against Dengue virus (DENV) and Rift Valley fever virus (RVFV), which recently have seen significant progress in putting forward new and improved vaccines, respectively. Experimental vaccines for filoviruses and Lassa virus (LASV) do exist but are hindered by a lack of financial interest and only partially or ill-defined correlates/mechanisms of protection that could be assessed in clinical trials.
除了少数例外，针对引起出血热的病毒的疫苗仍然无法获得或缺乏经过充分记录的疗效。在过去十年中，这并不是因为缺乏开发针对高致病性病毒的疫苗平台的能力，而是因为缺乏投资于有潜力成为成功疫苗的平台的意愿/兴趣。这方面的两个例外是针对登革热病毒 (DENV) 和裂谷热病毒 (RVFV) 的疫苗，最近在推出新的和改进的疫苗方面分别取得了重大进展。针对丝状病毒和拉沙病毒 (LASV) 的实验性疫苗确实存在，但由于缺乏财务兴趣以及在临床试验中可以评估的部分或定义不明确的保护相关性/机制而受到阻碍。
